Erroneously low results due to high nonspecific binding encountered with a radioassay kit that measures "true" serum vitamin B 12 . Am J Clin Pathol 74: 209-213, 1980. Subsequent to recent disclosures that low serum vitamin B, 2 results can appear normal using many of the current radioassay methods because of the presence of cobalamin (vitamin B 12 ) analogues in human serum, a number of radioassay kits have become available with modified intrinsic factor preparations and claims of measuring "true" vitaminB 12 . While evaluating two of these kits, one with R protein activity blocked and the other with R protein removed, the possibility was discovered that normal results could appear low owing to high nonspecific binding encountered with one of the methodologies. The problem of nonspecific binding was apparently due to incomplete inactivation of serum endogenous binding proteins and inadequate separation of free and bound radioisotope. The results demonstrate that "lower" vitamin B 12 values are not necessarily "truer" values, and therefore caution and critical evaluation should temper the haste to change to commercial radioassay procedures that claim to provide "true" vitamin B l2 levels. (Key words: Cobalamin analogues; Intrinsic factor preparations; Nonspecific binding; R protein; Radioassay kits; "True" serum vitamin B, 2 .) IN THE PAST, conventional methods for determining vitamin B 12 levels in serum consisted of various microbiologic assays, but these were time consuming and subject to a number of technical difficulties. In more recent years, bioassays have been largely replaced by rapid and reasonably sensitive radioisotopic competitive inhibition assays utilizing radioactive vitamin B 12 and native binding proteins such as intrinsic factor or the transcobalamines. and, whereas they are essentially inactive in the traditional bioassays, they can contribute to falsely elevated vitamin B 12 values when testing is performed using many of the current radioassay methods. It was shown that these procedures measure both vitamin B 12 and its analogues because they utilize intrinsic factor preparations that contain substantial amounts of a nonspecific binder known as R protein.
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Most recently, Kolhouse and associates 4 reported that cobalamin analogues are present in human serum and, whereas they are essentially inactive in the traditional bioassays, they can contribute to falsely elevated vitamin B 12 values when testing is performed using many of the current radioassay methods. It was shown that these procedures measure both vitamin B 12 and its analogues because they utilize intrinsic factor preparations that contain substantial amounts of a nonspecific binder known as R protein.
Subsequent to these disclosures, demands have been increasing for clinical laboratories to change their radioassay procedures in order to measure "true" vitamin B 12 levels. In turn, manufacturers of commercial kits have been modifying their products to mask or eliminate the R protein in their intrinsic factor preparations. This report concerns our experience with two of these modified commercial kits, one with R protein activity blocked (QuantaCount II Vitamin B-12 Radioassay),* and the other with R protein removed (Coat 57 Vitamin B12 Radioassay Kit).t While comparing these kits with each other and with a radioassay kit that measured "total" rather than " t r u e " vitamin B 12 4 -that of high nonspecific binding.
Materials and Methods
The protocols provided by the manufacturers were followed in all assays except those where modifications made in the Coat 57 protocol are noted. All three methodologies followed the general procedure of heating the serum samples in a 100 C boiling water bath under alkaline conditions in the presence of cyanide to release and convert endogenous cobalamin (vitamin B, 2 sites on a porcine intrinsic factor binder. Free and bound vitamin B, 2 were separated by adsorption of free vitamin B, 2 onto coated charcoal. The amount of bound vitamin B 12 remaining was determined by measuring the counts per minute (cpm) of radioactivity in the supernatant fraction. Major differences in the three kits as determined from package inserts are shown in Table 1 .
As noted, the Coat 57 protocol was modified for certain assays. In these instances dithiothreitol (DTT) was provided in the kit by the manufacturer, who also supplied special DTT preparations, identified only as "fresher" and "more purified." The hemoglobin-coated charcoal suspension used was a modification of that described by Lau and colleagues, 5 and consisted of 0.3% hemoglobin in a 2.5% charcoal solution. Crystalline human hemoglobin was obtained from the Sigma Chemical Company, § and activated charcoal powder ("Norit A") from Matheson Coleman and Bell.H The cobinamide preparation used (10 /tig/ml in borate buffer) was from Becton Dickinson.t Assay nonspecific binding tubes contained all test reagents except the intrinsic factor binder. The reaction volume was kept constant by the addition of 0.9% saline solution. In those Coat 57 assays where " O " standard was not included in the nonspecific binding tube, additional 0.9% saline solution was provided to maintain volume. Patient blanks contained patient serum and all the other required reagents, except that § Sigma Chemical Co., St. Louis, Missouri 63178.
11 Matheson Coleman and Bell, Norwood, Ohio 45212.
0.9% saline solution was substituted for the intrinsic factor binder.
Values for assay and patient serum nonspecific binding were calculated by expressing the sample cpm as a percentage of the total cpm.
Results

Comparative Assays Using Patient Samples
^ Forty-three patient serum samples chosen at random from our laboratory were assayed in duplicate for vitamin B 12 levels using the SimulTRAC and QuantaCount II kits. Thirty-six of these samples were also assayed using the Coat 57 kit (May 1978 protocol). Table 2 shows that the QuantaCount II kit provided "true" vitamin B 12 values averaging 20% lower than the "total" vitamin B 12 values obtained with the SimulTRAC kit. "True" vitamin B 12 values as measured by the Coat 57 kit averaged 43% lower than the SimulTRAC results. Comparing these data with those of Kolhouse and associates, 4 which show an average drop of 37% from "total" to "true" vitamin B, 2 using porcine material, it would appear that Coat 57 should be the kit of choice.
Comparison of Standards, Intrinsic Factor Preparations, and Nonspecific Binding
Since there was such a large difference in patient values obtained with the QuantaCount II and Coat 57 kits, both of which presumably measure'' true'' vitamin B 12 , standards, intrinsic factor preparations, and nonspecific binding were investigated. QuantaCount II and Coat 57 (May 1978 protocol) assays were performed using the intrinsic factor preparation from each kit while interchanging the standards, and conversely, standards from each kit were used while intrinsic factor preparations were interchanged. When the effect of nonspecific binding (discussion to follow) was subtracted, there was essentially no difference between the standards provided with each kit, as shown in Figure 1 . Figure 1 also shows that there was a difference between intrinsic factor preparations. The Coat 57 material was somewhat more sensitive than the QuantaCount II preparation. Table 3 shows that the Coat 57 kit (May 1978 protocol) had a serious nonspecific binding problem. Both the SimulTRAC and QuantaCount II protocols recommended inclusion of the " O " standard in the nonspecific binding tube, and the nonspecific binding values obtained were acceptable and comparable to a range of 1 -6% found in 16 patient serum blanks. The Coat 57 protocol did not allow for the " O " standard to be present in the nonspecific binding tube, and seemingly acceptable values of 3-5% were obtained when performing the assay in this manner. When the Coat 57 kit was used to measure its own " 0 " standard and the " O " standard from the QuantaCount II kit, nonspecific binding values were found to be in the range of 15-18% and 27-32%, respectively. Using the Coat 57 kit to test the same 16 patient samples evaluated with the QuantaCount II kit, nonspecific binding values in the range of 20-29% were found. Thus, the Coat 57 kit had been providing erroneously low patient results due to high nonspecific binding.
Modifications of Coat 57 Protocol
Addition ofDTT. During this study, the manufacturer of the Coat 57 kit had issued a revised protocol (February 1979 ) that provided for the addition of DTT to the buffer/tracer reaction mixture to a final concentration of p.2%. This modification, as shown in Table 4 , was found to lower dramatically the nonspecific binding previously experienced with the kit. However, the level of nonspecific binding was still unacceptably high.
Adjustments to DTT and Heating Times. Based on the improvement in nonspecific binding provided by the inclusion of 0.2% DTT in the Coat 57 assay, concentrations of 0.4% and 0.6% DTT were tried in the buffer/tracer reaction mixture, but this did not further lower the nonspecific binding. The use of "fresher" and "more purified" DTT preparations requested from the manufacturer had no further effect on the nonspecific binding, and neither did substitution of QuantaCount II kit DTT for Coat 57 kit DTT. Similarly, whether the specimens were heated at 100 Cforl5min, 30 min, or 45 min, the nonspecific binding remained in the ranges presented in the second column of Table 4 . Check on Assay pH. The assay pH was monitored at various stages of the procedure to be sure that the optimum of pH 9 or greater quoted by Kolhouse and associates 4 was maintained. Without the presence of DTT, the Coat 57 kit had a beginning to final pH range of 9.9 to 9.4. With 0.2% DTT present, the pH range was a more stable 9.4 to 9.2. The latter compared well with the SimulTRAC kit range of p H 9.3 to 9.2 and the QuantaCount II kit, which had a constant assay p H o f 9 . 3 .
Substitution of Charcoal. When QuantaCount II charcoal was substituted for that of Coat 57 in the assay, a further reduction in nonspecific binding was achieved. Since QuantaCount II charcoal also appeared to lower the maximum binding of the assay, a hemoglobin-coated charcoal suspension was tried. It achieved the same reduction in nonspecific binding without lowering the maximum binding. Table 4 shows that the Coat 57 charcoal used was therefore inadequate for the assay.
Addition of Cobinamide. Even though the " O " standard nonspecific binding values for all three kits had become comparable with the change in charcoal, as seen in Tables 3 and 4 , the patient serum blanks still averaged 7% for the Coat 57 kit with substituted charcoal, compared with average patient serum blanks of 3% and 4% for the SimulTRAC and QuantaCount II kits. Cobinamide (20 fxg) was added to the Coat 57 buffer/tracer/DTT reaction mixture, and Table 4 shows that this provided the final ingredient required to reduce the patient serum blanks to an acceptable level.
Discussion
The problem of nonspecific binding encountered with the Coat 57 kit and the modifications required to improve it illustrate some of the complexities involved in the measurement of " t r u e " vitamin B 12 using current commercial radioassay kits. Kolhouse and associates 4 treated their patient serum samples with heat and acid to release endogenous vitamin B, 2 , and this simultaneously precipitated protein. Endogenous binding proteins in the patient sera were thus removed, leaving in effect a protein-free filtrate for radioassay, which was performed at an alkaline pH. In the commercial kits we studied, these endogenous binding proteins were inactivated, rather than removed, at an alkaline p H . Our results show that, while heat alone could accomplish some of this inactivation, a combination of heat and DTT was more effective. In the case of the Coat 57 kit, it is consistent with the data to speculate that, in the absence of DTT, patient endogenous binding proteins were not entirely inactivated and they therefore bound some of the isotopically labeled vitamin B 12 added in the assay. This would cause the high nonspecific binding observed, resulting in falsely low patient values. Further inactivation of these endogenous binders occurred with the addition of DTT, but some activity still remained, leaving a small but significant problem with nonspecific binding. The addition of cobinamide reduced this effect to an acceptable level. In addition to the apparent incomplete elimination of endogenous binder activity, there was a charcoal-related problem of inadequate removal of free radioisotope. Any free radioisotope left behind to be counted with bound isotope would also contribute to the nonspecific binding observed.
Kolhouse and associates 4 addressed the problem of low vitamin B 12 results' appearing normal because of the presence of vitamin B 12 analogues, with emphasis on the importance of having a proper intrinsic factor preparation in the assay to overcome the problem. Our report calls attention to the possibility of normal results' appearing low owing to high nonspecific binding with the methodology used. The emphasis here is directed towards the rest of the reagents in the assay and the ability to properly inactivate the endogenous binding proteins in the patient samples, in addition to providing adequate separation of free and bound radioisotope. Overall, the results of this study demonstrate that "lower" vitamin B, 2 values are not necessarily "truer" values. Therefore, caution and critical evaluation should temper the haste to change to commercial radioassay procedures that claim to measure "true" vitamin B 12 levels.
